| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 527.101.903 $ | +206.024.334 $ | +445,9 % | 11 | 285.436.108 $ | +111.530.917 $ | +164,0 % | 7 | 243.969.941 $ | +89.184.559 $ | +49,8 % | 7 | ||||
| SPDR SER TR | → 0 | 105.377.250 $ | +102.847.250 $ | +4.065,1 % | 1 | ||||||||||
| KalVista Pharmaceuticals, Inc. | KALV | → 0 | 57.902.073 $ | +14.010.927 $ | +31,9 % | 1 | 43.891.146 $ | +27.285.202 $ | +164,3 % | 1 | |||||
| Abivax S.A. | ABVX | → 0 | Schwach | 33.686.716 $ | -23.248.121 $ | -40,8 % | 1 | 56.934.837 $ | +11.113.967 $ | +24,3 % | 1 | 45.820.870 $ | +45.820.870 $ | 1 | |
| Dianthus Therapeutics, Inc. /DE/ | DNTH | → 0 | Schwach | 54.946.284 $ | +24.033.179 $ | +77,7 % | 1 | 30.913.105 $ | +4.353.193 $ | +16,4 % | 1 | ||||
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 50.583.135 $ | +6.351.713 $ | +14,4 % | 1 | 44.231.422 $ | +27.357.345 $ | +162,1 % | 1 | ||||
| Celcuity Inc. | CELC | → 0 | Schwach | 47.071.678 $ | +9.656.012 $ | +25,8 % | 1 | 37.415.666 $ | +33.034.578 $ | +754,0 % | 1 | ||||
| UroGen Pharma Ltd. | URGN | → 0 | Neutral | 40.723.188 $ | +9.256.392 $ | +29,4 % | 1 | 31.466.796 $ | +3.758.793 $ | +13,6 % | 1 | ||||
| Immunome Inc. | IMNM | → 0 | Neutral | 40.465.580 $ | +16.274.589 $ | +67,3 % | 1 | ||||||||
| Kodiak Sciences Inc. | KOD | → 0 | Schwach | 37.812.372 $ | +9.205.881 $ | +32,2 % | 1 | ||||||||
| RHYTHM PHARMACEUTICALS, INC. | RYTM | → 0 | Neutral | 37.365.896 $ | +12.041.113 $ | +47,5 % | 1 | ||||||||
| Avidity Biosciences, Inc. | RNA | → 0 | 36.800.660 $ | +25.156.660 $ | +216,0 % | 1 | |||||||||
| Nuvalent, Inc. | NUVL | → 0 | 36.360.939 $ | +5.034.195 $ | +16,1 % | 1 | 31.326.744 $ | -869.760 $ | -2,7 % | 1 | 32.196.504 $ | +6.576.261 $ | +25,7 % | 1 | |
| Monte Rosa Therapeutics, Inc. | GLUE | → 0 | Schwach | 32.933.558 $ | +16.797.803 $ | +104,1 % | 1 | ||||||||
| Akero Therapeutics, Inc. | → 0 | 30.559.837 $ | -8.863.118 $ | -22,5 % | 1 | ||||||||||
| Erasca, Inc. | ERAS | → 0 | Neutral | 29.962.318 $ | +25.060.906 $ | +511,3 % | 1 | ||||||||
| INSMED Inc | INSM | → 0 | Neutral | 29.759.378 $ | +4.693.980 $ | +18,7 % | 1 | ||||||||
| 527.101.903 $ | +206.024.334 $ | +445,9 % | 11 | 285.436.108 $ | +111.530.917 $ | +164,0 % | 7 | 243.969.941 $ | +89.184.559 $ | +49,8 % | 7 | ||||